Authors: M. Gazouli, N. Nikiteas, NP. Anagnou, N. Kelekis, E. Efstathopoulos
Affilation: School of Medicine University of Athens, Greece
Pages: 396 - 398
Keywords: colorectal cancer, ck19, nanoprobes, quantum dots
The aim of the study was to develop and validate a QD-nanoprobe for the detection of CK19 protein for in vivo colorectal cancer molecular targeting. QDs with a maximum emission wavelength of 655 nm, were coated with streptavidin and functionalized with the biotinylated-CK19-antibody. In vitro binding affinity of these nanoprobes was evaluated in a panel of cell lines and clinical samples. For in vivo experiments, male NOD/SCID mice were used. Animals were injected with DLD-1 colorectal cancer cell. Upon reaching a tumor size of approximately 0.8 to 1 cm, were administered an into the tail vein injection of 10 pmol QD nanoparticles and CK19-QD nanoprobes and imaged at various time points. In vivo optical imaging was done using the IVIS imaging system 50 series. CK19-QD showed CK19-specific binding in vitro. Animals were euthanized after the injection of QD and CK19-QD. At the 3h time point, CK19-QD nanoprobes showed more prominent fluorescence when compared with QD nanoparticles. At 24h, both QD and CK19-QD fluorescence decreased to near-baseline levels. CK19-QD probes have good optical properties and biocompatibility for in vivo targeted imaging of colorectal cancer. Such approach promises to be highly desirable for molecular targeted research of gastrointestinal cancer.